Bank Of New York Mellon Corp Pliant Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $249,509 - $373,236	14,677 New	14,677 $283,000
Q3 2022 Nov 14, 2022	BUY	$7.67 - $24.23 $188,252 - $594,701	24,544 Added 232.2%	35,114 $733,000
Q2 2022 Aug 15, 2022	SELL	$4.11 - $8.75 $257,816 - $548,878	-62,729 Reduced 85.58%	10,570 $85,000
Q1 2022 May 11, 2022	SELL	$7.01 - $14.1 $1,142 - $2,298	-163 Reduced 0.22%	73,299 $513,000
Q4 2021 Feb 11, 2022	SELL	$12.27 - $18.26 $12,368 - $18,406	-1,008 Reduced 1.35%	73,462 $992,000
Q3 2021 Nov 12, 2021	BUY	$16.48 - $28.98 $250,166 - $439,916	15,180 Added 25.6%	74,470 $1.26 Million
Q2 2021 Aug 11, 2021	SELL	$28.05 - $37.69 $3.27 Million - $4.4 Million	-116,658 Reduced 66.3%	59,290 $1.73 Million
Q1 2021 May 13, 2021	BUY	$24.52 - $40.23 $2 Million - $3.28 Million	81,497 Added 86.28%	175,948 $6.92 Million
Q4 2020 Feb 09, 2021	BUY	$19.89 - $32.99 $164,311 - $272,530	8,261 Added 9.58%	94,451 $2.15 Million
Q3 2020 Nov 12, 2020	BUY	$21.54 - $29.53 $1.42 Million - $1.95 Million	66,048 Added 327.91%	86,190 $1.95 Million
Q2 2020 Aug 12, 2020	BUY	$21.3 - $35.26 $429,024 - $710,206	20,142 New	20,142 $653,000

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $600M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.